MOMETASONE FUROATE INTRA NASAL SPRAY FOR THE TREATMENT OF BILATERAL NASAL POLYPOSIS
Main Article Content
Objective: To know the safety and efficacy of Topical mometasone furoate nasal spray (NS) for the treatment of bilateral
Material and Methods: It was a randomized, double-blind, placebo controlled, parallel-group study, conducted in the
department of Otorhinolaryngology (Rhinology division) of Khyber Teaching Hospital, Peshawar-Pakistan. A total of
310 subjects 18 years or older with bilateral nasal polyps. Interventions: (1) A 200-?g dose of mometasone furoate NS
in the morning and matching placebo in the evening; (2) 200-?g doses of mometasone furoate NS in the morning and
evening; or (3) matching placebo in the morning and evening. All 3 regimens were administered as a nasal spray for 4
months, from September 2018 to December 2018.Primary end points were change from baseline to last assessment in
physician assessed bilateral polyp grade and change from baseline in subject-assessed congestion and/or obstruction
score averaged over the first month of treatment. Analysis of variance was used for all efficacy end points except for
change in bilateral polyp grade, for which baseline polyp grade was added as a covariate to the analysis of variance
model to account for any between-group baseline differences in this variable.
Results: Mometasone furoate NS doses of 200 ?g administered once or twice daily produced greater reductions in
bilateral polyp grade at the end point than placebo, with differences reaching statistical significance with twice daily
dosing (P=.04). Over 1 month, both mometasone furoate NS regimens produced statistically superior improvements
from baseline in congestion and/or obstruction score vs placebo (P=.01 for once-daily dosing; P.001 for twice daily
dosing). The drug was well tolerated.
Conclusion: Mometasone furoate NS is an effective and well-tolerated treatment for bilateral nasal polyposis in adults,
reducing nasal polyp size and symptoms of nasal congestion and/or obstruction.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.